Wyeth/Progenics Oral Methylnaltrexone Pushed Back A Year To Test New Formula
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies expect to submit an NDA for the oral formulation to treat opioid-induced constipation in 2009/2010 after initiating a new Phase II trial.
You may also be interested in...
Wyeth Plans Methylnaltrexone Studies In New Patient Populations
Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.
Wyeth Plans Methylnaltrexone Studies In New Patient Populations
Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.
Wyeth/Progenics File Methylnaltrexone Injection NDA For Opioid-Induced Constipation
Companies will meet with FDA in May to discuss new study for an oral formulation, Wyeth tells “The Pink Sheet” DAILY.